Genelabs Announces Issuance of U.S. Patent on DHEA Composition and Method
"I am very pleased to have this patent issue on our formulation of Prestara" stated James A.D. Smith, President and Chief Executive Officer. "We are currently working with the U.S. Food and Drug Administration on the design of a prospective phase III clinical trial to evaluate the ability of Prestara to reduce the incidence of flares in lupus patients. We are also in the process of seeking external project-directed funding for this trial, as we have earmarked most of our current financial resources for our three hepatitis C virus drug discovery programs, two of which are now partnered with premier pharmaceutical or biotechnology companies."
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.